Shattuck Labs initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Shattuck Labs (STTK) with an Overweight rating. The stock’s more than 800% rise over the last 12 months reflects enthusiasm for its DR3 and TL1A programs, with investors betting on differentiated efficacy and upcoming early-phase data that could de-risk key drug attributes, the analyst says in a research note. Continued clinical readouts across multiple autoimmune indications and interest in combination or bispecific approaches could further support upside, the firm says.